Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chapter 15

Antiviral Vaccines: Challenges and Advances

Ali H. Ellebedy, Rafi Ahmed
Emory University School of Medicine, Emory Vaccine Center and Department of Microbiology and Immunology, Atlanta, GA, United States

Chapter Outline

1 Introduction 283
2 Types of Currently Licensed Antiviral Vaccines 284
3 How Antiviral Vaccines Mediate Protection? 288
3.1 Antibodies 289
3.2 T Cells 290
4 Modern Approaches to Studying Immune Responses Induced by Antiviral Vaccines 290
5 Next Generation Vaccine Platforms 294
6 Harnessing the Technological Advances to Develop Vaccines Against Challenging and Emerging Viruses 295
6.1 The HIV Challenge 297
6.2 The Influenza Puzzle 299
6.3 The Quest for a Vaccine Against RSV 301
7 Summary 303
Acknowledgments References 304

1 INTRODUCTION

Vaccination is the most effective means of preventing and controlling viral infections. The eradication of smallpox and the significant progress made toward polio eradication are clear examples of the great impact of antiviral vaccines. However, viral infections remain a major public health threat and a significant cause of death. Most of the antiviral vaccines introduced over the past century were empirically developed. Poliomyelitis, measles, mumps, and rubella are examples of diseases that are now largely controlled thanks to these empirically developed vaccines.

The common factor among our most effective antiviral vaccines is that they were developed to mimic our natural immune response to the pathogen. For example, a single episode of measles confers lifelong immunity in the survivors. Hence, what we needed to do is induce a similar immune response.
It is when we have to do better than “mother nature” that we have been facing substantial challenges in developing successful vaccines. For example, the immune response against viruses such as HIV, influenza, and respiratory syncytial virus (RSV) is either inadequate or outpaced by the pathogen’s evolution. And while developing a broadly protective vaccine against such pathogens has been a colossal task, it is not impossible and similar missions have been successfully accomplished as in the case of anti-HBV and anti-HPV vaccines.

There is a growing list of emerging and reemerging viral infections against which an effective vaccine is yet to be developed. Recent technological advances in the areas of immunogen design, single cell transcriptomics, systems biology, gene delivery, epigenetics, nanoparticles, and adjuvants expanded our understanding of how vaccines work and provide potentially new platforms that could be harnessed to develop vaccines against challenging and emerging viral pathogens.

**2 TYPES OF CURRENTLY LICENSED ANTIVIRAL VACCINES**

1. **Live viral vaccines.** Live virus vaccines are prepared from viral strains that have been attenuated, but retain their ability to replicate in the human host and thus their ability to induce protective immune responses. Out of the 15 viruses against which antiviral vaccines are currently licensed in the United States, nine are live attenuated (Table 15.1). There are several immunological advantages for utilizing the live attenuated antiviral vaccine platform; (1) the replication of the attenuated vaccine strains in host cells allows for the potential activation of antigen-specific CD8+ T-cell responses; (2) the potential of eliciting a mucosal immune response (e.g., IgA), where the portal of entry for many viruses resides. Several methods have been used to attenuate virus strains in order to be safely used as human vaccines. One method depended on the use of viral strains that are specific to a different host as vaccine strain. The oldest example of such strategy is the use of cowpox virus to vaccinate humans against smallpox. Another strategy relied on attenuation of the virus by passaging it in unnatural host or cells. Examples of this approach are the development of 17D, the yellow fever vaccine strain and polioviruses. Introducing the virus via unnatural route is a strategy used to develop adenovirus Types 4 and 7 vaccine, which is given orally. Finally, generation of temperature sensitive mutants such as the live attenuated influenza vaccines.

2. **Inactivated whole viral vaccines.** Whole inactivated virus preparations are prepared by simply inactivating viral particles by heat, UV irradiation or by special chemical treatments. Formalin and beta-propiolactone are the most commonly used chemicals for this purpose. Vaccines against polioviruses and influenza were among the first to be prepared using this strategy. Immunogenicity of these viral preparations is usually robust as they contain
| Virus          | Number of serotypes included per disease | Platform       | Adjuvant | Route of administration | Test used to measure the correlate of protection | Trade name                      |
|---------------|------------------------------------------|----------------|----------|--------------------------|-----------------------------------------------|----------------------------------|
| Adenovirus    | 2 (Types 4 and 7)                        | Live attenuated| No       | Oral                     | Neutralization                               | No trade name, Barr Labs         |
| Hepatitis A   | 1                                        | Inactivated    | Aluminum salts | Intramuscular             | ELISA                                         | Havrix, GSK                     |
| Hepatitis A   | 1                                        | Inactivated    |           |                          |                                               | VAQTA, Merck                     |
| Hepatitis B   | 1                                        | VLP            |           |                          |                                               | Twinrix, GSK                     |
| Papillomavirus| 4 (Types 6, 11, 16, 18)                  | VLP            | Aluminum salts | Intramuscular             |                                               | Recombivax HB, Merck             |
|               | 9                                        |                |           |                          |                                               | Engerix-B, GSK                   |
|               | 2 (Types 16 and 18)                      |                | AS04     |                          |                                               | Gardasil, Merck                  |
|               |                                          |                |          |                          |                                               | Gardasil 9, Merck                |
|               |                                          |                |          |                          |                                               | Cervarix, GSK                    |
| Influenza     | 1 (2009 pH1N1)                           | Split          | No       | Intramuscular            | HA^I^                                         | No trade name, CSL               |
|               |                                           | Live attenuated| No       | Intranasal               |                                               | No trade name, MedImmune         |
|               |                                           | Split          | No       | Intramuscular            |                                               | No trade name, ID Biomedical     |
|               |                                           | Subunit        | No       |                          |                                               | No trade name, Novartis          |
|               |                                           | Split          | No       |                          |                                               | No trade name, Sanofi Pasteur    |

(Continued)
| Virus | Number of serotypes included per disease | Platform      | Adjuvant | Route of administration | Test used to measure the correlate of protection | Trade name                                      |
|-------|-----------------------------------------|---------------|----------|-------------------------|-----------------------------------------------|------------------------------------------------|
| 1 (H5N1) | Split                                   | No            |          |                          |                                               | No trade name, Sanofi Pasteur                  |
|       | Split                                   | AS03          |          |                          |                                               | No trade name, ID Biomedical                  |
| 3 (H1N1, H3N2, and type B) | Subunit                                 | MF59          |          | Intranasal               |                                               | FLUAD, Novartis                                |
|       | Split                                   | No            |          | Intramuscular            |                                               | AFLuria, CSL                                   |
|       | Split                                   | No            |          | Intramuscular            |                                               | FluLaval, ID Biomedical                       |
|       | Live attenuated                         | No            | Intranasal|                          |                                               | FluMist, MedImmune                             |
|       | Split                                   | No            | Intramuscular|                          |                                               | Fluarix, GSK                                  |
|       | Subunit                                 | No            | Intramuscular|                          |                                               | Fluvirin, Novartis                             |
|       | Subunit                                 | No            | Intramuscular|                          |                                               | Agriflu, Novartis                              |
|       | Split                                   | No            | Intramuscular or Intradermal|                          |                                               | Fluzone, Sanofi Pasteur                       |
|       | Subunit                                 | No            | Intramuscular|                          |                                               | Flucelvax, Novartis                           |
|       | Recombinant                              | No            | Intramuscular|                          |                                               | Flublok, Protein Sciences                     |
| 4 (H1N1, H3N2, and two type B strains) | Live attenuated | No            | Intranasal|                          |                                               | FluMist Quadrivalent, MedImmune               |
|       | Split                                   | No            | Intramuscular|                          |                                               | Fluarix Quadrivalent, GSK                    |
|       | Split                                   | No            | Intramuscular|                          |                                               | Fluzone Quadrivalent, Sanofi Pasteur          |
|       | Split                                   | No            | Intramuscular|                          |                                               | Fluzone Quadrivalent, ID Biomedical           |
| Disease                          | Number of serotypes | Platform       | Adjuvant          | Route of administration | Test used to measure the correlate of protection | Trade name                  |
|---------------------------------|---------------------|----------------|-------------------|-------------------------|-----------------------------------------------|----------------------------|
| Japanese Encephalitis           | 1                   | Inactivated    | No                | Subcutaneous            | Neutralization                                | Ixiaro, Intercell Biomed   |
| Measles and mumps               | 1                   | Live attenuated| No                | Subcutaneous            | Neutralization                                | JE-Vax, BIKEN-Osaka        |
| Measles, mumps, and rubella     | 1                   | Live attenuated| No                | Subcutaneous            | Neutralization (measles and mumps) Immunoprecipitation (rubella) | M-M-Vax, Merck             |
| Measles, mumps, rubella, and varicella | 1                  | Live attenuated| No                | Subcutaneous            | Neutralization (measles and mumps) Immunoprecipitation (rubella) FAMA gp ELISA (rubella) Immunoprecipitation (rubella) | M-M-R II, Merck           |
| Poliovirus                      | 3 (Types 1, 2, 3)   | Inactivated    | No                | Intramuscular or Subcutaneous Neutralization | IPOL, Sanofi Pasteur                          |
| Rabies                          | 1                   | Inactivated    | No                | Intramuscular           |                                               | Imovax, Sanofi Pasteur    |
| 1                               |                      |                |                   |                         |                                               | RabAvert, Novartis         |
| Rotavirus                       | 1                   | Live attenuated| No                | Oral                    | Serum IgA                                      | ROTARIX, GSK               |
| 5 [G1, G2, G3, G4, and P1A(8)] | Live attenuated     | No             | Oral              |                         |                                               | Rotateq, Merck             |
| Smallpox                        | 1                   | Live attenuated| No                | Percutaneous            | Neutralization                                | ACAM2000, Sanofi Pasteur  |
| Varicella                       | 1                   | Live attenuated| No                | Subcutaneous            | FAMA gp ELISA                                  | Varivax, Merck             |
| Yellow fever                    | 1                   | Live attenuated| No                | Subcutaneous            | Neutralization                                | YF-Vax, Sanofi Pasteur    |
| Zoster                          | 1                   | Live attenuated| No                | Subcutaneous            | CD4 T cell Lymphoproliferation                 | Zostavax, Merck            |

*aVaccines that have been licensed, but their production has been discontinued are not included.

bHAI stands for hemagglutination inhibition assay.

cMeasles, mumps, and rubella are also licensed to be used in combination with other antibacterial and antipolio virus vaccines under different trade names that are not included in this table.
multiple pathogen-associated molecular patterns (PAMPs) that could engage several of the host innate immune receptors such as the toll-like receptors (TLRs).\textsuperscript{12} For polio, an incident of incomplete inactivation of the vaccine preparation resulted in an outbreak of paralytic poliomyelitis in the United States, the so-called “Cutter Incident.”\textsuperscript{13,14} Hence, safety of such preparations has always been a concern.

3. **Subunit vaccines.** Due to the increased risk of reactogenicity associated with whole inactivated virus vaccine preparations, purified preparations that contain the main targets of protective immune responses were developed.\textsuperscript{15} Subunit vaccines that contain the surface glycoproteins of influenza and hepatitis B viruses are currently licensed (Table 15.1). Subunit vaccines show an improved reactogenicity profile compared to whole inactivated virus preparations, but this is usually at the expense of the immunogenicity of the vaccine. When administered with adjuvants, immune responses to these vaccines can be significantly enhanced.\textsuperscript{16}

4. **Recombinant viral proteins.** The advance in methods of protein manufacturing made it possible to express desired viral proteins on a large scale to be used as vaccine antigens. Bacterial, yeast, insect, and mammalian cell lines have been used for this purpose.\textsuperscript{17} A recombinant vaccine that contains the main surface glycoprotein of influenza viruses, the hemagglutinin or HA, Flublok,\textsuperscript{18} has recently been licensed in the United States (Table 15.1). As discussed later in the chapter, some recombinant viral proteins such as the surface antigen of hepatitis B viruses tend to form virus-like particles upon expression.

5. **Virus-like particles (VLPs).** VLPs are multimeric structures assembled from viral structural proteins. They often display viral surface proteins in a high-density repetitive manner on their surface, which may play a role in the enhanced immunogenicity observed with this kind of vaccines compared to recombinant viral proteins.\textsuperscript{19–22} In 1986, the first antiviral VLP vaccine (against hepatitis B) had been licensed.\textsuperscript{23} The vaccine is based on the hepatitis B surface antigen or HBsAg, which upon expression in yeast forms spherical VLPs that are then adsorbed onto alum as adjuvant. Recently, another antiviral VLP vaccine against human papillomavirus has been licensed.\textsuperscript{22}

### 3 HOW ANTIVIRAL VACCINES MEDIATE PROTECTION?

Viral infections can be broadly classified into three main categories depending on the nature of the infection:

1. Acute infections caused by antigenically stable viruses. Infection with- or vaccination against such viruses provides a lifelong immunity to clinical reinfection. Examples of such viruses include smallpox, yellow fever, measles, mumps, rubella, and polio. Developing effective vaccines against these viruses has been relatively a straightforward process.
2. Acute infections caused by rapidly mutating viruses. The immunity acquired against such viruses through infection or vaccination is usually short-lived because of the antigenic changes, and recurrent immunization is often required. The clearest example for such viruses is influenza. 24

3. Chronic infections caused by rapidly mutating viruses. HIV and HCV are prime examples for such viruses. Developing vaccines against such viruses have proved to be a very daunting task. 25–27

Two main effector arms of the adaptive immune response that are induced by antiviral vaccines mediate protection against viral infections: antibodies and T cells. 1,28 While we will briefly discuss these two arms later in the chapter, it is important to understand that other immune effectors such as cytokines secreted by innate immune cells activated by the vaccine itself or by coadministered adjuvants could also directly contribute to controlling the viral burden. Also, the initial innate immune recognition of the vaccines/adjuvants is essential not only for triggering the adaptive immune responses, but also for determining the quality and duration of such responses. 28

3.1 Antibodies

Given the speed with which most viruses replicate, possessing protective levels of preformed antibodies is the best strategy to protect against most viral infections. Therefore, a major immunological goal for antiviral vaccines is to elicit high and durable levels of antigen-specific antibodies. 29 Preferably these antibodies are induced at the portal of virus entry. To date, all human vaccines that have shown considerable success in combating viral infections depend on antibodies as the primary mediators of protection. 1 The process of generating these antibodies starts when a vaccine antigen encounters and binds to its specific B cell. In the presence of cognate CD4 T-cell help, these vaccine specific B cells start to expand. 30 Some of the activated B cells differentiate into plasmablasts whose function is to secrete an early protective wave of antigen-specific antibodies. 30 In a primary vaccination, those early antibodies are mostly IgM and bind to the vaccine antigen with a relatively low affinity. A subset of the activated B cells will continue expanding forming specially organized structures in the secondary lymph nodes known as germinal centers (GCs). 30 GCs are where vaccine-specific B cells with the highest antigen binding affinity are preferentially selected and also where the majority of antibody isotype-switching from IgM to IgG and IgA occurs. 31

Antibodies can protect against viral infections via several ways:

1. When induced to sufficient levels, antibodies prevent infection by blocking the binding of viruses to their receptors on host cells. These are called “neutralizing” antibodies, and their target epitopes lie primarily within the surface glycoproteins of enveloped viruses or the capsid proteins of non-enveloped ones. The target epitopes of neutralizing antibodies are usually conformational.
2. Opsonization and phagocytosis of viral particles by neutralizing and non-neutralizing antibodies that bind to the surface of viral particles.

3. Lysing infected cells that express viral antigens on their surface via the complement pathway or through antibody-dependent cellular cytotoxicity (ADCC). For ADCC, cells mediating the lysis of infected cells such as natural killer (NK) cells recognize the antibody labeling infected cells via Fc receptors.\(^{32}\)

The cells responsible for the maintenance of antigen-specific serum antibody levels following vaccination and infection are long-lived plasma cells. These cells are generated during the germinal center reaction and reside mainly in the bone marrow.\(^{33-36}\)

### 3.2 T Cells

The main two subsets of T cells are CD4\(^+\) and CD8\(^+\) T cells. Through at least one of these two subsets T cells participate in the protection mediated by all antiviral vaccines. The main function of T cells is to provide help to B cells (CD4\(^+\)) or clear the infection (CD8\(^+\)), and not to prevent the infection. In contrast to antibodies that recognize epitopes in 3-dimensional conformation, T cells recognize linear peptides from the infecting agent that are expressed on MHC molecules on the surface of virus-infected cells. Some of these peptides come from viral proteins that do not exhibit extensive antigenic variation making T cells an important mechanism of protection against rapidly evolving viruses.\(^{37}\)

CD4\(^+\) T cells contribute to antiviral vaccine effectiveness in several ways; secreting cytokines such as IFN-\(\gamma\) and TNF and supporting the activation of B cells and CD8\(^+\) T cells (Th1); secretion of IL-4, IL-5, IL-13, and other cytokines to support B-cell activation and differentiation (Th2); triggering the formation and maintenance of the GC reaction via the expression of CD40L and secretion of IL-21 (Tfh). CD8\(^+\) T cells, on the other hand, clear virus infected cells by directly killing those cells (through the release of perforins and granzymes) or indirectly by secreting inflammatory cytokines. CD8\(^+\) T-cells can control viral burden and thus limit the severity of the disease. In the United States, there is currently no licensed antiviral vaccine that works solely via the induction of T cells, but they significantly contribute to the protective effect of several antiviral vaccines such as those against the measles and zoster viruses.

### 4 MODERN APPROACHES TO STUDYING IMMUNE RESPONSES INDUCED BY ANTIVIRAL VACCINES

1. **Systems vaccinology.** Systems biology is the integrative analysis of all the components involved in a complex biological process.\(^{38}\) It includes the analysis of the genes (eg, transcriptomics), the molecules (eg, proteomics) and cells (eg, multiparameter flow cytometry) that were “perturbed” in the course
of a certain biological process such as an active immune response. Systems vaccinology refers to the use of systems biological approaches in analyzing human immune responses to vaccination. Advantages of using systems vaccinology approaches include; (1) gaining new insights about the mechanisms of antiviral vaccine-mediated immunity; (2) defining new molecular signatures triggered by the immune response to various vaccines and adjuvants; (3) the potential use of those molecular signatures as alternative correlates of protection. Moreover, applying systems biology approaches highlighted the important role played by the early innate immune responses in triggering adaptive immune responses to various antiviral vaccines. This role is usually overlooked when assessing the effectiveness of such vaccines using traditional correlates of protection (Table 15.1). Analysis of the immune response to the yellow fever YF-17D vaccine was one of the earliest examples of utilizing systems vaccinology and it provided a proof of concept for such approach. The approach was later applied to other antiviral vaccines such as those against influenza. In summary, these exciting advances highlight the potential of systems biology to transform our understanding of not only how antiviral vaccines work, but also the mechanisms of immune regulation in general.

2. Multiparameter flow cytometry. The introduction of flow cytometry has revolutionized how we analyze immune responses. It allowed us to examine not only the physical parameters of various immune cells, such as cell size and granularity at different states, but also the expression levels of many proteins either on the cell surface or inside the cells simultaneously. These analyses provide us with enormous insights about a variety of biological processes that an immune cell experiences such as activation, proliferation, differentiation and death when responding to a foreign antigen. At the beginning the number of fluorescent dyes (which are conjugated to antibodies so that each dye could be assigned to one molecule) that could be used simultaneously was limited to one or two. This number has dramatically expanded (up to 18) over the past two decades. These advances came from the introduction of novel fluorescent dyes that provided additional excitation and emission spectra to be used. Perhaps one of the most important insights that came from flow cytometric analyses is the defining of the multiple lineages of B and T cells that are elicited by various antiviral vaccines. Also, how the differentiation status and fates of these lineages change over time.

The number of parameters that can be measured per cell has recently been expanded to more than 40 by the integration of mass spectrometry with single-cell fluidics (eg, CyTOF). In CyTOF, antibodies are labeled with heavy metal ion tags instead of fluorochromes. Another major advantage of CyTOF is the elimination of signal interference resulted from spectral overlap of the various fluorescence dyes. Reports using these new technologies are already revealing new insights about the complexity and interconnectedness of the different subsets of virus-specific T cells generated after infection.
3. Single-cell transcriptomics. While the aforementioned systems approaches have provided exceptional insights on how our immune system works, some of them measure only the “average” of the response from sometimes a highly heterogeneous cell population. Gene expression analyses for example are performed using total mRNA purified from highly heterogeneous cell populations. In the latter scenario, the end result of the analysis would probably be biased toward the most abundant fraction of the heterogeneous cell population because of their larger contribution to the overall RNA content. Therefore, identifying rare subsets of cells using such technologies is arguably impossible.\(^{42}\) Single-cell RNA sequencing (RNA-seq) is an important extension of the gene expression arrays technologies. It enabled us to interrogate the genome-wide expression profile of individual cell mRNA in an unbiased way. In addition, single-cell RNA-seq revealed some other transcriptional features in single cells, such as splice variants, allele-specific expression, and the potential discovery of previously uncharacterized genes.\(^{42}\)

4. Epigenetic regulation of immune responses. Epigenetics refer to histones and DNA modifications, which regulate the access of different transcription factors and polymerases to transcriptional regulatory elements in chromatin.\(^{45}\) Such modifications regulate gene expression and provide cells with a mechanism to retain acquired transcriptional programs throughout cell division. Given the essential role of epigenetics in deciding and maintaining cell fate, a huge amount of interest has recently been given to studying the role of epigenetics in immune responses to viral infections and vaccines. There are several aspects through which immune responses to antiviral vaccines could be modified via epigenetics; (1) defining the epigenetic programs associated with memory B and T cells with optimal quality; (2) directing the differentiation of immune cells into the most desired fate (eg, Th1 vs. Th2 CD4 T cells); (3) reversing an undesirable fate of antigen-specific cells (eg, rejuvenation of exhausted CD8 T cells in chronic viral infections).\(^{45}\) Characterization of the gene expression and epigenetic programs associated with antiviral vaccine-induced memory B and T cells will provide further insight into the protective quality of the poised effector recall response.\(^{45}\)

5. Next generation sequencing (NGS) of the B and T cell receptor repertoires. Next generation sequencing (also referred to as deep sequencing) has significantly impacted how we analyze many biological phenomena;\(^{46}\) immune response is no exception. In regard to immune responses to antiviral vaccines, deep sequencing has affected both sides of the equation: the virus/vaccine side and the adaptive immune side. Most RNA viruses such as HIV and influenza exist as quasispecies and the introduction of deep sequencing technology has afforded us a higher resolution look at such diversity instead of analyzing individual viruses.\(^{1}\) Each clonal pool of antigen-specific B or T cell share a distinct junction region that is formed at the site of the B-cell receptor (BCR) heavy or T-cell receptor (TCR) beta gene segments ligation.\(^{47}\)
Interrogating the B-cell repertoire by deep sequencing allowed us to study the diversity of B-cell responses to viral infections and vaccinations.\textsuperscript{46} By diversity here we refer to how many distinct clonal pools are participating in the B- or T-cell response to a particular vaccine. This is particularly important when analyzing responses to vaccines against highly variable viruses such as influenza and HIV. Against such viruses it is better to have a polyclonal response that is directed against several epitopes than a focused response. Moreover, tracking B-cell clonal pools that secrete antibodies of desired specificity or quality has helped in studying the ontogeny and evolution of such responses.\textsuperscript{48} Similar analyses have been performed on the alpha and beta chain of the TCRs.\textsuperscript{49}

6. \textit{Generation of human monoclonal antibodies (mAbs).} More than a 100 years ago, Emil von Behring developed passive immunotherapy using serum to treat infections, such as diphtheria and tetanus and was awarded the Nobel prize in Physiology or Medicine in 1901.\textsuperscript{50} The advent of hybridoma technology in the mid-1970s introduced the concept of generating a monoclonal antibody with a single defined specificity.\textsuperscript{51} Over the past two decades, tremendous efforts have gone into developing technologies to generate human mAbs. The currently most widely used methodologies to generate human mAbs are:

a. Phage display libraries: As the name indicates, phages are designed to express single-chain variable antibody fragments (scFvs) or antigen-binding fragments (Fabs) on their surface and screened for binding to the desired antigen. The libraries are constructed from the variable genes of B cells isolated from vaccinated individuals or from convalescent patients. This method has been successfully used to generate neutralizing mAbs against many viruses including West Nile, rabies, severe acute respiratory syndrome (SARS) virus, hepatitis A, HIV, Ebola, yellow fever, hepatitis C, measles and influenza.\textsuperscript{52} A major drawback of this method is that it cannot be used to examine the repertoire or the immunodominance hierarchy of the antigen-specific B-cell response as the antibody fragments displayed were generated by random pairing of the BCR heavy and light chains and not from a naturally existing pairing.\textsuperscript{53}

b. B-cell immortalization: B cells can be immortalized by Epstein–Barr virus (EBV) mediated transformation.\textsuperscript{54} Immortalized B cells can then be stimulated to secrete antibodies and those antibodies are screened for the desired specificity. B-cell pools secreting the desired antibody are then cloned by limiting dilution into single cells and the BCR genes are sequenced. This method has been used to generate mAbs against many viruses including influenza, HIV, SARS, dengue, and RSV.\textsuperscript{55–58} While this method is effective in isolating mAbs from rare memory B cells,\textsuperscript{59} it is labor-intensive, as it requires the screening of thousands of immortalized memory B cells in order to isolate few mAbs with the desired specificity.
c. Single cell cloning and expression of mAbs: This is the most recent technology and also the most efficient.\textsuperscript{60,61} In this approach, the heavy and light chain genes of single-cell sorted B cells are amplified and cloned into antibody expression vectors. Single antigen-specific B cells can be sorted by flow cytometry based on their surface phenotype (e.g., sorting of plasmablasts from blood following vaccination)\textsuperscript{62} or based on their binding to a desired antigen.

Human mAbs have expanded our understanding of human B-cell responses to viral infections. Through the generation of mAbs following various viral infection and vaccination we were able to map the viral targets of our most protective immune responses. Most importantly, they revealed some of the subdominant epitopes within viral proteins that are now being extensively examined, as discussed later in the chapter, as targets for broadly neutralizing mAbs and potential cores for new immunogens.

5 NEXT GENERATION VACCINE PLATFORMS

1. \textit{Structure-based immunogen design}. As mentioned earlier, the design an immunogen to be used as an antiviral vaccine has always been an empirical process. The immunogen was picked based on its ability to elicit a detectable protective immune response. While this process was sufficient for many viruses, for some challenging viruses such as HIV and influenza, a deeper analysis of the epitopes targeted by neutralizing antibodies was needed.\textsuperscript{63} The traditional way of determining the amino acid residues within a viral protein that are recognized—and thus mediate virus neutralization—by a certain mAb is the generation of viral escape mutants. This method was instrumental in mapping the major neutralizing epitopes within the influenza HA molecule.\textsuperscript{64} However, this method has several drawbacks; (1) some neutralizing mAbs fail to generate escape mutants such as the influenza broadly neutralizing mAbs recognizing the HA stem region (discussed later in the chapter) and therefore could not be mapped using this approach; (2) the increased risk and logistic difficulties associated with the generation of escape mutants against certain viruses, such as the highly pathogenic avian influenza viruses and Ebola; (3) given that the majority of neutralizing mAbs recognize conformational epitopes so identifying a single or few amino acid residues that contribute to binding does not provide a complete picture; (4) a change of an amino acid residue in an escape mutant does not necessarily mean that this residue is the point of contact between the viral protein and the mAb. A change of the epitope conformation induced by the change of an adjacent amino acid residue could also be responsible for the generation of an escape mutant.

In 1990, the first crystal structure of a viral glycoprotein-antibody complex was published.\textsuperscript{65} Solving such structures for many viral glycoproteins has allowed us to examine the binding of antibodies to their respective
epitopes at the atomic level. More importantly, it provided the basis for rationally designing viral immunogens that could—at least theoretically—induce an immune response enriched with antibodies with a desired specificity. This idea has recently been tested with partial success in the efforts to generate targeted antibody responses to HIV, RSV, and influenza. These early experiments have also revealed that more work is needed to fully understand how these complex epitopes are recognized by B cells in vivo and how to minimally design an immunogen without interrupting its stability as a protein or the antigenicity of the epitope.

2. DNA- and RNA-based vaccines. The concept of using naked DNA as a vaccine was introduced in the early 1990s. It rapidly gained traction mainly due to its simplicity and versatility. While the early clinical trials demonstrated the safety of DNA vaccines, it also revealed that they were poorly immunogenic. The immunogenicity of DNA vaccines has been improved through different methods; (1) improving the efficiency of DNA delivery to enhance the cellular uptake of the plasmid DNA; (2) the use of adjuvants either in physical form or encoded on separate plasmids; (3) optimizing the sequence of the DNA vaccine to enhance the expression and immunogenicity of the encoded protein. DNA vaccines against a variety of viruses are now being tested at different stages of clinical trials.

Advances in the methods of mRNA synthesis and stabilization have paved the way for the possibility of using mRNA as vaccine platforms. The ability of mRNA to stimulate several of the innate immune receptors (e.g., TLR3 and TLR7/8) gives them an intrinsic adjuvant activity. The approach has been boosted by the recent introduction of self-amplifying RNA strategy, which works by delivering the alphavirus genes encoding the RNA replication machinery along with the recombinant viral target antigen resulting in enhanced antigen expression.

3. Vector-based vaccines. Vectored-based vaccines could be considered a type of DNA vaccines where an attenuated virus or bacterium is used to introduce microbial DNA to host cells. The most commonly used virus vectors are adenoviruses, alphaviruses, and poxviruses. As for bacteria, strains belonging to Bacillus Calmette-Guerin, Listeria monocytogenes, and Salmonella typhi are being tested as vectors for human vaccines.

6 Harnessing the Technological Advances to Develop Vaccines Against Challenging and Emerging Viruses

Viral pathogens against which an effective vaccine is yet to be licensed can be broadly grouped into two categories; challenging viruses and emerging viruses. Examples for challenging viruses are HIV, HCV, RSV, CMV, HSV-2, EBV, and dengue. For a variety of reasons, developing an effective vaccine against these viral pathogens has been a formidable task despite the tremendous
Great amounts of resources have gone into developing a vaccine against HIV, but this mission has proved to be the most arduous so far (challenges and prospects are discussed later in the chapter). As for influenza, effective vaccines against seasonal and potentially pandemic influenza virus strains have been licensed. However, these vaccines (as discussed later in the chapter) do not offer broad protection against these rapidly evolving viruses. Vaccine candidates against RSV and dengue have now entered advanced stages of clinical testing (Table 15.2).

**TABLE 15.2 Some of the Antiviral Vaccine Candidates That are in Advanced Stage of Development (Phase 2 or Beyond)**

| Virus  | Name of vaccine candidate | Manufacturer or sponsor | Development phase | References |
|--------|---------------------------|-------------------------|-------------------|------------|
| HCV    | Ad6NSmut                  | GSK                     | Phase 1/2         | [70–72]    |
|        | TG4040                    | Transgene               | Phase 2           |            |
|        | GI-5005                   | GlobalImmune            | Phase 2           |            |
| CMV    | ASP-0113                  | Astellas Pharma         | Phase 3           | [73]       |
| SV-2   | GEN-003                   | Genocea Biosciences     | Phase 2           | [74]       |
|        | HerpV                     | Agenus                  | Phase 2           | [75]       |
| HIV    | AGS-004                   | Argos Therapeutics      | Phase 2           | [76–83]    |
|        | HIV recombinant           | GSK                     | Phase 2           |            |
|        | AIDSVAX                   | GeoVax                  | Phase 2           |            |
|        | Vacc-4x                   | Bionor Pharma           | Phase 2           |            |
|        | VRC-hIVADV014-00-VP       | GenVec/VRC              | Phase 2           |            |
| RSV    | RSV F Protein             | GSK                     | Phase 2           | [84,85]    |
|        | RSV F Nanoparticle        | Novavax                 | Phase 3           |            |
| Dengue | Dengvaxia                 | Sanofi Pasteur          | Phase 3           | [86,87]    |
|        | DENVax                    | Inviragen               | Phase 2           |            |
| Ebola  | ChAd3-ZEBOV               | GSK/PHAC                | Phase 2/3         | [89]       |
|        | VSV-EBOV                  | New Link Genetics/Merck | Phase 2/3         |            |
| Norovirus | G1-I/GII-4 VLP       | Takeda Vaccines         | Phase 2           | [90]       |

*aThis list is not exhaustive. For example, it does not include vaccine candidates for viruses against which successful vaccines have already been licensed such as influenza, HPV, Zoster, and rabies.*
Emerging viral pathogens include Ebola, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), hendra, nipah, Marburg, chikungunya, lassa, Crimean-Congo hemorrhagic fever, and zika viruses. Infections with most of these viruses are limited to certain endemic areas, which in turn make the decision of developing a vaccine against such viruses not an economically favorable one. However, in the wake of the 2014 massive Ebola outbreak that ravaged West Africa this perception could change. For Ebola, recent studies suggest that robust immune responses could be detected in convalescent patients, indicating that developing a protective vaccine against this pathogen is doable. Indeed, many vaccine candidates have shown promising results in clinical trials. Two of these candidates are ready for Phase 3 testing. Other antiviral vaccines that are in advanced stages of clinical testing include vaccines developed against CMV and norovirus. Later in the chapter we will discuss the challenges facing developing a vaccine against HIV, influenza (universal), and RSV, and how recent technological advances could help in overcoming such challenges.

6.1 The HIV Challenge

Efforts to develop a vaccine against HIV started in the mid-1980s and the fact that there is still no licensed vaccine yet despite the plethora of resources invested shows the enormity of the task. The challenges that impede developing a vaccine against HIV stem from the following points:

1. Like most RNA viruses, HIV viruses continually mutate and evolve leading to the emergence of new variants even within an infected individual. This necessitates that for any vaccine to be successful, it has to elicit an immune response with enough breadth to protect against such extensive diversity.

2. The correlates of protection against HIV infection are not well established. A common factor for viruses against which a vaccine has successfully been developed is that we know which immune effector mediates protection. Correlates of protection are usually defined by analyzing immune responses in individuals who have recovered from infection or showed less susceptibility to such infection. Complete recovery from HIV infection is not common occurrence, if at all. This is at least partially because the virus infects CD4 T cells, which orchestrate the two arms of adaptive immune responses: B cells and CD8 T cells.

3. There is a knowledge gap in regard to which protein/portion of the viral proteins is the most antigenic and immunogenic and thus best suited as a vaccine antigen. Also, whether a specific structural conformation is required for such protein to elicit a protective immune response is not clear.

The disappointing results of the early vaccines that were designed to solely induce CD8+ T-cell responses has refocused anti-HIV vaccine efforts on generating protective broadly neutralizing antibody responses. This notion was augmented by the modest success of the RV144 HIV vaccination trial conducted in
Thailand in which subjects were primed with a replication-defective canarypox viral vector expressing HIV gp120, gag, and pol proteins, and then later boosted with the gp120 protein. The rate of HIV infection among subjects who received the experimental vaccine was 30% lower than that in volunteers who received the placebo. A correlation of protection with the antibody response to the V2 region of the HIV envelope protein was later established.

In vivo, anti-HIV antibodies could protect in several ways; (1) neutralize cell-free virions; (2) block cell-to-cell transmission; (3) clear infected cells by antibody-dependent cell-mediated cytotoxicity or ADCC; (4) block transcytosis of the virions from the lumen to the basolateral side of mucosal cells (Fig. 15.1). The RV144 trial observations resulted in a sharp increase in the number of broadly neutralizing anti-HIV human mAbs that are being isolated and characterized. Sequence analysis of these antibodies and structural examination of their interactions with HIV antigens at the atomic level have strengthened our understanding of how these broadly neutralizing antibodies

FIGURE 15.1 Potential mechanisms of neutralizing antibody-mediated protection against HIV. There are at least four different mechanisms by which anti-HIV neutralizing antibodies could block the virus. First, they can block the initial attachment of the virus to its receptor/coreceptor on the target cells. Second, they can block viral spread through cell-to-cell transmission. Third, they can aid in the clearance of infected cells through Fc-dependent mechanisms such as antibody-dependent cell-mediated cytotoxicity. Fourth, anti-HIV antibodies could inhibit the passage of HIV-1 from the lumen to the basolateral pole (HIV-1 transcytosis). (Source: Adapted from Ref. [97].)
work. For example, we now know that broadly neutralizing antibodies are more likely to have either an unusually long CDR3 loop or an extremely high rate of somatic hypermutations..Extensive research efforts are currently focused on learning how to elicit such antibodies by vaccination. This target is being pursued from different angles:

1. The use of structurally inspired immunogens that mimic the epitopes of the broadly neutralizing mAbs. The hope is to get a B-cell immune response that is dominated by such antibodies. Early trials indicate that additional structural requirements may be needed for the desired epitopes to be recognized in vivo other than just presenting the epitopes in the right conformation.

2. Possible need for a special immunization strategy that depends on sequentially exposing the immune system to different, but closely related HIV envelope proteins. The idea is to mimic how the immune system of chronically HIV-infected individuals experiences a rapidly evolving virus and ends up developing broadly neutralizing antibodies in a subset of them. Extensive deep sequencing analysis of the ontogeny of some of the broadly neutralizing antibodies has allowed us to dissect the affinity maturation steps required to attain such levels of reactivity.

3. Examining the evolution of the viral genome in infected individuals by deep sequencing. This approach would help us define the characteristics of the immunogens that should be used in the sequential immunization strategy discussed earlier.

In summary, new technological advances have taught us that; (1) HIV exists as a swarm of viruses and evolves rapidly within infected individuals (deep sequencing analysis); (2) our immune system is capable of generating very potent and broadly neutralizing mAbs that could combat such viral diversity (generation human mAbs); and (3) we can design new immunogens to enrich B cell responses to HIV vaccines with the broadly neutralizing antibodies (structure-based immunogen design).

6.2 The Influenza Puzzle

The earliest trials to develop an influenza vaccine date back to the 1940s, shortly after the isolation of the first human influenza virus in 1933. It was an inactivated whole virus preparation developed by the US military to be used in World War II. Although these early vaccines were protective, controlling infections mediated by this respiratory pathogen continues to represent a formidable challenge. The dilemma stems from the ever-evolving nature of influenza viruses, which enables the viruses to escape preexisting immune surveillance. Moreover, effective vaccines against influenza viruses work by eliciting antibody responses that primarily target the globular head of the HA, which is the most variable among virus proteins. Therefore, it has been necessary to perform an annual revision of the antigens included in human seasonal influenza vaccines.
to ensure that they match the circulating influenza strains. Currently, seasonal influenza vaccines include antigens from three (H1N1, H3N2, and an influenza B) or four (H1N1, H3N2, and two influenza B) human influenza virus strains. The need for a broadly protective influenza vaccine is clearly demonstrated by the occasional failure of these seasonal influenza vaccines to control the annual epidemics of influenza viruses, which result in about 3–5 million cases of severe illness, and up to 500,000 deaths worldwide. In a more serious scenario, influenza viruses cause occasional pandemics when an antigenically novel virus spills into the human population or when, as in the case of the 2009 pandemic H1N1 virus, an influenza virus that has ceased to circulate among humans for decades reemerges.

The major neutralizing epitopes are located around the receptor-binding domain within the influenza HA globular head region (Fig. 15.2). While antibodies targeting such epitopes are protective, they are mostly strain-specific and lack the broad neutralizing activity required to protect against different influenza subtypes. Structural analysis of a number of the recently isolated broadly neutralizing human HA-specific mAbs revealed that they bound to a conserved domain within the HA stem region (Fig. 15.2). These mAbs were isolated by phage display libraries or by direct cloning of single cell sorted plasmablasts following influenza infection or vaccination. Unlike the case for HIV, influenza broadly neutralizing antibodies could be detected following infection and vaccination. Therefore, it remains puzzling that despite being repeatedly exposed to such conserved domains of influenza HA either in the form of vaccination or natural infection that influenza remains a serious public health problem. One possible—among many—explanation for this puzzle is that the concentration of HA stem-specific antibodies is too low to prevent infection.
This notion is supported by the observation that mAbs targeting the stem region are weaker in general than those targeting the head epitopes in terms of in vitro neutralization potency.

The question then is how to boost stem-specific responses to levels that are protective in vivo. Recent data suggest that conventional seasonal vaccines induced B-cell responses are dominated by those targeting the HA head region. Therefore, new immunogens would be needed to refocus the responses on those targeting the HA stem region. The use of immunogens comprised of globular head region HA molecules derived from viruses which have not been widely circulating in the human population, such as H5N1 avian influenza viruses, combined with a stem region that is conserved among the strains can change the dominant immune response from head focused to stem focused. The globular head region of H5 is significantly different from the circulating human viruses while the stem region is largely conserved. The idea is to engage stem-specific memory B cells with minimal interference of the head specific ones. While this strategy did indeed succeed in boosting the stem-specific responses, questions regarding whether this boost is enough to afford protection in vivo are yet to be addressed. In addition, further boosting with H5 in the aforementioned trial restored the globular head immunodominance of B-cell responses suggesting that the globular head region might be intrinsically more immunogenic than its stem counterpart. Similar to HIV, efforts are now focused on designing structure-based immunogens that present the broadly neutralizing epitopes (those within the HA stem and the within the receptor-binding domain) to the immune system in the most relevant conformation.

6.3 The Quest for a Vaccine Against RSV

As discussed earlier, the gold standard for designing a successful antiviral vaccine is to mimic natural infection. This scenario could not be applied in the case for RSV because natural RSV infection provides limited protection from reinfection. Therefore, developing a protective vaccine against RSV has been a daunting task. It has been a global public health priority for over 5 decades. While antigenic variability is a major obstacle in developing a broadly protective vaccine against HIV and influenza, there are only two serotypes of RSV and cross-reactive antibodies could be readily detected in human sera. The major hurdles that hindered the development of a licensed vaccine against RSV are:

1. Vaccine-enhanced disease: This phenomenon was first noted when a formalin-inactivated vaccine candidate (FI-RSV) was developed and tested in infants and children in the late 1960s and the immunogenicity results were promising. However, upon natural RSV infection, 80% of the FI-RSV-vaccinated subjects were hospitalized, whereas only 5% of the control group required admission, and two children died.
FIGURE 15.3  RSV vaccines currently in pipeline. (Source: This RSV vaccine snapshot is reproduced with permission from PATH and can be found at http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/.)
2. The formidable task of getting the right balance between vaccine safety and immunogenicity/efficacy especially in the most vulnerable and highest priority target population, infants.\(^1\)

3. The lack of ideal animal models making clinical trials—which are expensive and time consuming—an imperative measure to assess candidate vaccines. Additionally, the clinical endpoints in evaluating an RSV vaccine efficacy are not very specific as the disease symptoms are shared with many other respiratory viral infections.\(^1\)

Based on the epidemiology and burden of RSV disease there are four target populations for RSV vaccination; (1) infants (<6 months); (2) children (6–24 months); (3) pregnant women; (4) the elderly.\(^117,118\) Each of these populations presents its own challenges in terms of how their immune systems respond to various vaccine candidates. There are several types of RSV vaccines that have been developed and many others are in the pipeline (Fig. 15.3). Many of these vaccines are still in the preclinical stage. Four types of vaccine platforms are being tested in Phase 1, 2, or 3 trials (Fig. 15.3); live attenuated virus vaccines; particle-based vaccines (VLPs); subunit vaccines; and vector-based vaccines.\(^123\) Each of these vaccine platforms has advantages and disadvantages,\(^117,118\) but they mostly share that they focus on eliciting antibody response to RSV F glycoprotein.\(^123\) Palivizumab, which is a humanized mAb specific to the F glycoprotein, is a proof of principle that neutralizing antibodies could provide protection against hospitalization.\(^124,125\) Palivizumab is licensed to be used in infants at high risk of severe disease.\(^124,125\)

Recently, the structural insights gained by solving the atomic structure of the pre- and postfusion forms of the F proteins have invigorated RSV vaccine development efforts.\(^126–130\) We now know that many of the neutralizing F-specific antibodies that did not bind the postfusion form of the F protein are actually specific to the prefusion form. Moreover, a novel antigenic site, termed Ø, was revealed. Antibodies targeting this epitope show a more potent neutralization capacity compared to palivizumab.\(^1\) The efforts are now focused on preparing physically stable vaccine candidates comprised of the native F protein trimer in its prefusion form.\(^131\)

7 SUMMARY

There are multiple factors that contribute to the lack of a licensed protective vaccine against any particular virus. Most of these factors originate from the nature of the virus itself. Examples include: (1) viruses that exhibit extensive genetic variations (eg, influenza); (2) viruses that evolved multiple mechanisms for evading host immune detection and response (eg, HCV and HSV); (3) viruses that integrate their genomes in that of the host (eg, HIV); (4) viruses that are capable of developing latency (HSV). Some factors stem from the inability of the host to protect against infection (and reinfection) due to the inadequacy of the immune response (eg, RSV). Other factors that are unrelated to both virus and
host include the lack of animal models that are suitable for evaluating the efficacy of vaccine candidates and economical considerations. Early antiviral vaccine success stories (e.g., smallpox, rabies, and yellow fever) were based on empirical efforts in which vaccines were derived from either a live attenuated form of the virus or inactivated whole virus. It is clear that such approaches are not enough to address the current challenges. Developing an effective vaccine against many of the currently challenging viruses would require an integrative effort from scientists representing various disciplines. For example, public health studies would be needed to assess the disease burden in different populations in order to define the most vulnerable ones. Virological studies would be important for generating viral vaccine strains that lack immune evasion capacity, for example. Immunologists would define which arms of the immune response are needed to achieve protection. Bioinformaticians would need to work very closely with immunologists in order to transform high-throughput data and analyses into concrete, useful knowledge. Structural analyses would help in identifying important immune targets and how to rationally design immunogens that elicit maximal immune responses to such targets. Vaccinologists would then assess vaccine candidates in preclinical and clinical trials. Finally, engaging the pharmaceutical industry would be essential for scaling up the production of the final product.

ACKNOWLEDGMENTS

This work was funded in part by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) contract number HHSN266200700006C (to RA). AE is supported by the training grant (T32AI074492) from the National Institute of Allergy and Infectious Diseases.

REFERENCES

1. Graham BS. Advances in antiviral vaccine development. *Immunol Rev* 2013;255:230–42.
2. Henderson DA. The eradication of smallpox—an overview of the past, present, and future. *Vaccine* 2011;29(Suppl. 4):D7–9.
3. Centers for Disease, C. & Prevention. Progress toward eradication of polio—worldwide, January 2011–March 2013. *MMWR Morb Mortal Wkly Rep* 2013;62:335–8.
4. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. *Vaccine* 2000;18:1436–47.
5. Minor PD. Live attenuated vaccines: historical successes and current challenges. *Virology* 2015;479–480:379–92.
6. Sanchez-Sampedro L, et al. The evolution of poxvirus vaccines. *Viruses* 2015;7:1726–803.
7. Bonaldo MC, Sequeira PC, Galler R. The yellow fever 17D virus as a platform for new live attenuated vaccines. *Hum Vaccin Immunother* 2014;10:1256–65.
8. Kitchen LW, Vaughn DW. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. *Vaccine* 2007;25:7017–30.
9. Wareing MD, Tannock GA. Live attenuated vaccines against influenza: an historical review. *Vaccine* 2001;19:3320–30.
10. Hannoun C. The evolving history of influenza viruses and influenza vaccines. *Expert Rev Vaccines* 2013;12:1085–94.
11. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. *Vaccine* 1996;14:735–46.
12. Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. *Trends Biotechnol* 2011;29:294–306.
13. Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. *J Infect Dis* 2014;210(Suppl. 1):S380–9.
14. Brown F. Review of accidents caused by incomplete inactivation of viruses. *Dev Biol Stand* 1993;81:103–7.
15. Tan M, Jiang X. Subviral particle as vaccine and vaccine platform. *Curr Opin Virol* 2014;6:24–33.
16. O’Hagan DT, Fox CB. New generation adjuvants—from empiricism to rational design. *Vaccine* 2015;33(Suppl. 2):B14–20.
17. van Oers MM, Pijlman GP, Vlak JM. Thirty years of baculovirus-insect cell protein expression: from dark horse to mainstream technology. *J Gen Virol* 2015;96:6–23.
18. Yang LP. Recombinant trivalent influenza vaccine (flublok(R)): a review of its use in the prevention of seasonal influenza in adults. *Drugs* 2013;73:1357–66.
19. Chroboczek J, Szurgot I, Sztolcsa E. Virus-like particles as vaccine. *Acta Biochim Pol* 2014;61:531–9.
20. Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. *Trends Biotechnol* 2013;31:654–63.
21. Fernandes F, Teixeira AP, Carinhas N, Carrondo MJ, Alves PM. Insect cells as a production platform of complex virus-like particles. *Expert Rev Vaccines* 2013;12:225–36.
22. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. *Expert Rev Vaccines* 2013;12:129–41.
23. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. *Vaccine* 2008;26:6266–73.
24. Ellebedy AH, Webby RJ. Influenza vaccines. *Vaccine* 2009;27(Suppl. 4):D65–8.
25. Johnston MI, Fauci AS. An HIV vaccine—challenges and prospects. *N Engl J Med* 2008;359:888–90.
26. Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? *Semin Liver Dis* 2014;34:79–88.
27. Drummer HE. Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. *Front Microbiol* 2014;5:329.
28. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. *Nat Immunol* 2011;12:509–17.
29. Dormer T, Radbruch A. Antibodies and B cell memory in viral immunity. *Immunity* 2007;27:384–92.
30. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. *Nat Rev Immunol* 2012;12:24–34.
31. Victora GD, Nussenzweig MC. Germinal centers. *Annu Rev Immunol* 2012;30:429–57.
32. Pincetic A, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat Immunol* 2014;15:707–16.
33. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. *Immunity* 1998;8:363–72.
34. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. *Curr Opin Immunol* 1998;10:252–8.

35. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. *N Engl J Med* 2007;357:1903–15.

36. Manz RA, Cassese G, Thiel A, Radbruch A. Long-lived plasma cells survive independent of antigen. *Curr Top Microbiol Immunol* 1999;246:71–4 discussion 74–75.

37. Valkenburg SA, et al. Immunity to seasonal and pandemic influenza A viruses. *Microbes Infect* 2011;13:489–501.

38. Nakaya HI, Pulendran B. Vaccinology in the era of high-throughput biology. *Philos Trans R Soc Lond B Biol Sci* 2015;370.

39. Querc TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. *Nat Immunol* 2009;10:116–25.

40. Nakaya HI, et al. Systems biology of vaccination for seasonal influenza in humans. *Nat Immunol* 2011;12:786–95.

41. Chattopadhyay PK, Roederer M. Cytometry: today’s technology and tomorrow’s horizons. *Methods* 2012;57:251–8.

42. Chattopadhyay PK, Gierahn TM, Roederer M, Love JC. Single-cell technologies for monitoring immune systems. *Nat Immunol* 2014;15:128–35.

43. Nolan GP. Flow cytometry in the post fluorescence era. *Best Pract Res Clin Haematol* 2012;24:505–8.

44. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. *Immunity* 2012;36:142–52.

45. Youngblood B, Hale JS, Ahmed R. Memory CD8 T cell transcriptional plasticity. *F1000Prime Rep* 2015;7:38.

46. Georgiou G, et al. The promise and challenge of high-throughput sequencing of the antibody repertoire. *Nat Biotechnol* 2014;32:158–68.

47. Boyd SD, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. *Sci Transl Med* 2009;1:12ra23.

48. Liao HX, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature* 2013;496:469–76.

49. Turchaninova MA, et al. Pairing of T-cell receptor chains via emulsion PCR. *Eur J Immunol* 2013;43:2507–15.

50. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. *Nat Rev Microbiol* 2004;2:695–703.

51. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975;256:495–7.

52. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. *Nat Biotechnol* 2007;25:1421–34.

53. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. *Nat Rev Immunol* 2012;12:709–19.

54. Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. *Nature* 1977;269:420–2.

55. Habersater F, et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. *Virology* 1998;249:32–41.

56. Buchacher A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein–Barr virus transformation for peripheral blood lymphocyte immortalization. *AIDS Res Hum Retroviruses* 1994;10:359–69.
57. Traggiai E, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871–5.
58. Corti D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010;120:1663–73.
59. Yu X, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008;455:532–6.
60. Wardemann H, et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374–7.
61. Smith K, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009;4:372–84.
62. Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008;453:667–71.
63. Karlsson Hedestam GB, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008;6:143–55.
64. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982;31:417–27.
65. Bizebard T, et al. Crystallization and preliminary X-ray diffraction studies of a monoclonal antibody Fab fragment specific for an influenza virus haemagglutinin and of an escape mutant of that haemagglutinin. J Mol Biol 1990;216:513–4.
66. Ferraro B, et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011;53:296–302.
67. Weiner DB. RNA-based vaccination: sending a strong message. Mol Ther 2013;21:506–8.
68. Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res 2013;2:97–105.
69. da Silva AJ, Zangirolami TC, Novo-Mansur MT, Giordano Rde C, Martins EA. Live bacterial vaccine vectors: an overview. Braz J Microbiol 2014;45:1117–29.
70. Di Bisceglie AM, et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology 2014;147:119–31.
71. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456–62.
72. Kelly C, et al. Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans. Hepatology 2015.
73. Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines 2015;14:341–50.
74. Skoberne M, et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. J Virol 2013;87:3930–42.
75. Wald A, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011;29:8520–9.
76. Achenbach CJ, et al. Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multi-centre randomised clinical trial. Lancet HIV 2015;2:e82–91.
77. Goepfert PA, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2014;210:99–110.
78. Harrer T, et al. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine 2014;32:2657–65.
79. Hayes P, et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. *Clin Vaccine Immunol* 2013;20:397–408.

80. Mehendale S, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. *PLoS One* 2013;8:e55831.

81. Pollard RB, et al. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2014;14:291–300.

82. Routy JP, Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. *Immunotherapy* 2010;2:467–76.

83. Wecker M, et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. *Clin Vaccine Immunol* 2012;19:1651–60.

84. Glenn GM, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. *J Infect Dis* 2016;213(3):411–22.

85. Nolan T, et al. Prevalence and incidence of respiratory syncytial virus and other respiratory viral infections in children aged 6 months to 10 years with influenza-like illness enrolled in a randomized trial. *Clin Infect Dis* 2015;60:e80–9.

86. Guy B, Briand O, Lang J, Saville M, Jackson N. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. *Vaccine* 2015;33:7100–11.

87. Osorio JE, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. *Lancet Infect Dis* 2014;14:830–8.

88. McElroy AK, et al. Human Ebola virus infection results in substantial immune activation. *Proc Natl Acad Sci USA* 2015;112:4719–24.

89. Roca A, Afolabi MO, Saidu Y, Kampmann B. Ebola: a holistic approach is required to achieve effective management and control. *J Allergy Clin Immunol* 2015;135:856–67.

90. Treanor JJ, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate—reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. *J Infect Dis* 2014;210:1763–71.

91. Tramont EC. Towards a preventive HIV vaccine—lessons from history. *AIDS Res Hum Retroviruses* 1994;10(Suppl. 2):S181–5.

92. Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV vaccine research for treatment and prevention. *Front Immunol* 2014;5:417.

93. Greenspan NS. Design challenges for HIV-1 vaccines based on humoral immunity. *Front Immunol* 2014;5:335.

94. Excler JL, Robb ML, Kim JH. HIV-1 vaccines: challenges and new perspectives. *Hum Vaccin Immunother* 2014;10:1734–46.

95. Corey L, et al. Immune correlates of vaccine protection against HIV-1 acquisition. *Sci Transl Med* 2015;7:310rv317.

96. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med* 2012;366:1275–86.

97. Mouquet H. Antibody B cell responses in HIV-1 infection. *Trends Immunol* 2014;35:549–61.

98. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 2009;326:285–9.

99. Pejchal R, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. *Science* 2011;334:1097–103.
100. Wu X, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 2010;329:856–61.
101. Huang J, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. *Nature* 2012;491:406–12.
102. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. *Nat Immunol* 2015;16:571–6.
103. Doria-Rose NA, Joyce MG. Strategies to guide the antibody affinity maturation process. *Curr Opin Virol* 2015;11:137–47.
104. Mann JK, Ndung’u T. HIV-1 vaccine immunogen design strategies. *Virol J* 2015;12:3.
105. Webby RJ, Webster RG. Are we ready for pandemic influenza? *Science* 2003;302:1519–22.
106. Ellebedy AH, Ahmed R. Re-engaging cross-reactive memory B cells: the influenza puzzle. *Front Immunol* 2012;3:53.
107. Caton AJ, Raymond FL, Brownlee GG, Yewdell JW, Gerhard W. Antigenic variation in influenza virus. *Biochem Soc Trans* 1983;11:435–41.
108. Ekiert DC, et al. Antibody recognition of a highly conserved influenza virus epitope. *Science* 2009;324:246–51.
109. Sui J, et al. Structural and functional bases for a broad-spectrum neutralization of avian and human influenza A viruses. *Nat Struct Mol Biol* 2009;16:265–73.
110. Ekiert DC, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. *Science* 2011;333:843–50.
111. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science* 2011;333:850–6.
112. Ellebedy AH, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. *Proc Natl Acad Sci USA* 2014;111:13133–8.
113. Lingwood D, et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. *Nature* 2012;489:566–70.
114. Ledgerwood JE, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. *Lancet Infect Dis* 2011;11:916–24.
115. Wei CJ, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. *Science* 2010;329:1060–4.
116. Kanekiyo M, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. *Nature* 2013;499:102–6.
117. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. *Curr Opin Virol* 2013;3:468–74.
118. Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in RSV vaccine development. *Expert Rev Vaccines* 2014;13:333–44.
119. Sato M, Wright PF. Current status of vaccines for parainfluenza virus infections. *Pediatr Infect Dis J* 2008;27:S123–5.
120. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med* 2005;352:1749–59.
121. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child* 1986;140:543–6.
122. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. *Immunol Res* 2007;39:225–39.
123. Anderson LJ, et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. *Vaccine* 2013;31(Suppl. 2):B209–15.
124. Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. *Clin Dev Immunol* 2013;2013:359683.

125. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. *Expert Opin Biol Ther* 2011;11:1455–67.

126. Yin HS, Paterson RG, Wen X, Lamb RA, Jardetzky TS. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. *Proc Natl Acad Sci USA* 2005;102:9288–93.

127. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. *Nature* 2006;439:38–44.

128. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. *J Virol* 2011;85:7788–96.

129. Swanson KA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. *Proc Natl Acad Sci USA* 2011;108:9619–24.

130. McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. *Science* 2013;340:1113–7.

131. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. *Curr Opin Immunol* 2015;35:30–8.